Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Documenti analoghi

• Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia
  di: Mark Gillies, et al.
  Pubblicazione: (2026)
• Macular Atrophy in the Better‐Seeing Eye of Australian Patients Treated for Neovascular Age‐Related Macular Degeneration
  di: Yohei Hashimoto, et al.
  Pubblicazione: (2025)
• The Long Journey of Treatment for Wet Macular Degeneration, Is It Worth It?
  di: Mark Gillies
  Pubblicazione: (2025)
• Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort
  di: Zachary George Angus, et al.
  Pubblicazione: (2026)
• Treat and Extend Anti‐VEGF Treatment Regimens for Neovascular Age‐Related Macular Degeneration: To Stop or Not to Stop?
  di: Praveen J. Patel
  Pubblicazione: (2025)